30 results
8-K
EX-99.1
COGT
Cogent Biosciences Inc
2 Nov 23
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results
9:18am
, the company’s mission of bringing best-in-class therapies to patients with genetically defined diseases, plans to present clinical results from all
8-K
EX-99.1
nubgtidexmsml qf4
8 Aug 23
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results
8:14am
8-K
EX-1.1
r705f
8 Jun 23
Entry into a Material Definitive Agreement
4:31pm
8-K/A
EX-1.1
25w1sh5q7 rfbroofve
16 Jun 22
Entry into a Material Definitive Agreement
5:03pm
8-K
EX-1.1
ijy84zf1pp
15 Jun 22
Entry into a Material Definitive Agreement
5:18pm
POS AM
ob8ploa6npy6 y9z
6 May 22
Prospectus update (post-effective amendment)
4:33pm
8-K
EX-1.1
9hsffqif6stla dvz8
2 Dec 20
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-99.1
1bnavyd2o4v9oohf
9 Nov 20
Cogent Biosciences Reports Third Quarter 2020
7:33am